Zydus Lifesciences has secured approvals from the United States Food and Drug Administration (USFDA) for both Enzalutamide capsules and tablets, strengthening its position in the oncology market. These approvals address the critical need for effective treatments for prostate cancer, a leading cause of cancer-related deaths in men.
Enzalutamide Capsules Approval
Zydus Lifesciences received final USFDA approval to manufacture Enzalutamide capsules (40 mg). These capsules are androgen receptor inhibitors specifically indicated for treating patients with metastatic castration-resistant prostate cancer. According to IQVIA MAT July 2024 data, Enzalutamide capsules (40 mg) had annual sales of $869.4 million in the United States.
The capsules will be manufactured at the group’s formulation manufacturing facility in Moraiya, Ahmedabad.
Enzalutamide Tablets Tentative Approval
In addition to the capsule approval, Zydus also received tentative approval from the USFDA to manufacture Enzalutamide tablets (40 mg and 80 mg). These tablets are indicated for treating patients with both castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer.
As per IQVIA MAT July 2024 data, Enzalutamide tablets (40 mg and 80 mg) had annual sales of USD 1,417.2 million in the US.
The tablets will be manufactured at the Group's manufacturing site at SEZ, Ahmedabad.
Significance of the Approvals
These approvals mark a significant milestone for Zydus Lifesciences, bringing their total to 400 approvals with over 465 Abbreviated New Drug Applications (ANDAs) filed since the commencement of the filing process in FY 2003-04. The addition of generic Enzalutamide formulations to their portfolio will provide more accessible and affordable treatment options for patients suffering from prostate cancer.
Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.
